PETALING JAYA: Duopharma Biotech Bhd
’s latest contract win brings its approved products purchase list (APPL) contract to 99 products, with a total estimated value of RM682.3mil through to end-December 2026.
TA Research is optimistic about the group’s prospects, projecting a 41.2% rise in earnings to RM88.4mil, driven by higher demand, lower active pharmaceutical ingredient costs and better cost efficiencies. Duopharma also stands to benefit from the stronger ringgit, as the new APPL contract is based on a rate of RM4.70 per US dollar.
TA Research has kept its earnings projections for the financial year 2025 (FY25) to FY27, reiterating a “buy” call on the stock with an unchanged target price of RM1.62 per share, based on 16 times the FY26 earnings per share.
